Neurologist explains why vaccinated people are still contracting and spreading COVID-19 at a high rate
Friday, September 10, 2021 by: Nolan Barton
Tags: animal research, antibodies, badhealth, badmedicine, Big Pharma, coronavirus, covid-19, COVID-19 vaccine, herd immunity, immune escape, innate immunity, internal immunity, mucosal immunity, natural immunity, pharmaceutical fraud, research
11KVIEWS
(Natural News) Dr. Michael Segal, a neurologist and neuroscientist, explained in a
recent article published by the Wall Street Journal why people
vaccinated against the Wuhan coronavirus (COVID-19) are still contracting and spreading the
disease at a high rate.
Segal wrote that the
vaccines only stimulate internal immunity but do nothing to address mucosal
immunity. Internal immunity protects the inside of the body while
mucosal immunity provides the first line of defense by protecting the nose
and mouth, and by doing so also reduces spread to others.
He said that all COVID-19
vaccines “are largely ineffective at stimulating the secretion of a particular
form of antibodies called Immunoglobulin A (IgA) into our noses that occurs
after actual infection with a virus.” Meanwhile, those who have contracted and
recovered from the disease have both mucosal and internal immunity. They have
what they call a natural immunity from the disease.
A recent study in Israel
proved that natural immunity is better than getting vaccinated. The researchers
found that vaccinated people were 13 times as likely to become infected and 27
times as likely to have symptomatic infections as people with natural immunity.
(Related: COVID-19 natural
immunity vs vaccine-induced immunity guide.)
Recovered COVID-19 patients retain broad and durable immunity to the
disease
An Emory University study published in the journal Cell Reports Medicine found
that most people who have
recovered from COVID-19 retain a broad and durable immunity to the
disease, including
some degree of protection against its variants.
Rafi Ahmed, the lead author
of the paper, said that the findings disproved early reports during the
pandemic that protective neutralizing antibodies did not last in COVID-19
patients.
“The study serves as a
framework to define and predict long-lived immunity to SARS-CoV-2 after natural
infection. We also saw indications in this phase that natural immunity could
continue to persist,” Ahmed said. SARS-CoV-2 is the virus that causes COVID-19.
After people recover from
infection with a virus, the immune system retains a memory of it. Immune cells
and proteins that circulate in the body can recognize and kill the pathogen if
it’s encountered again, protecting against disease and reducing illness
severity.
The study involved 254
COVID-19 patients between 18 to 82 years old, who provided blood samples at
various points for a period of over eight months beginning April last year.
About 71 percent of the patients had mild disease, 24 percent experienced
moderate illness and five percent had severe disease.
Ahmed and his team found
that most of the patients who recovered mounted a strong and wide-ranging
immune response to the virus for at least the 250-day duration of the study.
Long-term immune
protection involves
several components. Antibodies recognize foreign substances like viruses and
neutralize them. Different types of T cells help recognize and kill pathogens.
B cells make new antibodies when the body needs them.
All of these immune system
components have been found in people who recovered from COVID-19. But the
details of this immune response and how long it lasts after infection have been
unclear. Scattered reports of reinfection with SARS-CoV-2 have raised concerns
that the immune response to the virus might not be durable.
A study published on Jan. 6
in Science analyzed immune cells and antibodies from almost
200 people who had been exposed to SARS-CoV-2 and recovered.
Drs. Daniela Weiskopf,
Alessandro Sette and Shane Crotty from the La Jolla Institute for Immunology
led the study. It was funded in part by the National Institute of
Allergy and Infectious Diseases (NIAID) and the National
Cancer Institute (NCI).
Time since infection ranged
from six days after symptom onset to eight months later. More than 40
participants had been recovered for more than six months before the study
began. About 50 people provided blood samples at more than one time after
infection.
The researchers found
durable immune responses in the majority of people studied.
Antibodies against the
spike protein of SARS-CoV-2 were found in 98 percent of participants one month after symptom onset. As seen in previous studies, the number
of antibodies ranged widely between individuals. But their levels remained
fairly stable over time, declining only modestly at six to eight months after
infection.
Experts
recommend that coronavirus be allowed to circulate throughout population
Some experts are now recommending
that the virus be allowed to
circulate throughout the population, with precautions taken for vulnerable individuals.
“We don’t have anything
that will stop transmission, so I think we are in a situation where herd
immunity is not a possibility and I suspect the virus will throw up a new
variant that is even better at infecting vaccinated individuals,” Andrew
Pollard, director of the Oxford Vaccine Group, told a parliamentary panel last
month.
Pollard argued that if mass
testing was not stopped, “the UK could be in a situation of continually
vaccinating the population.” He said that only those with symptoms should be
tested while others should go about their daily lives.
Iceland’s state
epidemiologist voiced similar sentiments.
“We really cannot do
anything else but allow the virus to take its course in order for the
population to achieve herd immunity,” said Porolfur Gudnason, chief
epidemiologist of Iceland’s Directorate of Health. (Related: Study: 2 in 3 Indians
have natural immunity against coronavirus, meaning “herd immunity” is already
achieved.)
“We need to try to
vaccinate and better protect those who are vulnerable but let us tolerate the
infection. It is not a priority now to vaccinate everyone with the third dose.”
Mass
vaccinations need to stop
Governments need to stop mass vaccination
drives to get a shot at herd immunity.
In March, vaccine expert
Dr. Geert Vanden Bossche said in an open letter that ongoing mass vaccination
drives are “likely to further enhance adaptive immune escape as none of the
current vaccines will prevent replication or transmission of viral variants.”
Immune escape is a term
used to describe when the host is no longer able to recognize and
counter a pathogen such as a relevant variant or mutant of SARS-CoV-2.
“The more we use these
vaccines for immunizing people in the midst of a pandemic, the more infectious
the virus will become,” Vanden
Bossche wrote. “With increasing infectiousness comes an increased likelihood of
viral resistance to the vaccines.”
Under this scenario,
manufacturers will be forced to refine or improve the vaccines, which will
then increase the selection pressure.
Selection pressure is a
term used to describe the process that helps an organism or pathogen to evolve
in ways that make it better adapted to its changing environment. An antibiotic
resistance, which is caused by overuse of antibiotic drugs, is a good example
of selection pressure.
The virus will effectively
outsmart the highly specific antigen-based vaccines that are being used and
tweaked. Vanden Bossche said the “much more infectious” viral variants are
already examples of immune escape from our innate immunity.
Follow Pandemic.news for more news and information related to the coronavirus pandemic.
Sources
include:
